Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog

Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine

Volumn 53, Issue 3, 2006, Pages 129-133

  Serres, F ^a   Nicolle, A P ^b   Tissier, R ^c,d   Gouni, V ^b   Pouchelon, J L ^b,d   Chetboul, V ^b,d  

^a Unité Pédagogique de Médecine

^b Unité de Cardiologie d'Alfort   (France)

^c Unité de Pharmacie Toxicologie

^d ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; TADALAFIL;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; DOG; DOG DISEASE; MALE; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

ANIMALS; CARBOLINES; DOG DISEASES; DOGS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS; DIROFILARIA IMMITIS;

EID: 33644924338     PISSN: 0931184X     EISSN: 14390442     Source Type: Journal    
DOI: 10.1111/j.1439-0442.2006.00800.x     Document Type: Article

References (23)

1. ®) as a therapy for pulmonary hypertension in dogs. Proceedings of the Baltimore 2005 ACVIM congress J. Vet. Intern. Med. 19 399 488
2. Bonagura J. D. M. R. Grady J. D. Powers D. S. Herring 1986 Quantitative cross sectional echocardiography in the normal dog Vet. Radiol. 27 34 49
3. Boon J. A. 2003 Veterinary Echocardiography, Two-dimensional and M-mode Imaging (Handy Reference) Teton Newmedia Jackson, MS
4. Chetboul V. N. Athanassiadis D. Concordet A. Nicolle D. Tessier M. Castagnet J. L. Pouchelon H. P. Lefebvre 2004 Observer-dependent variability of quantitative clinical endpoint: example of canine echocardiography J. Vet. Pharmacol. Ther. 27 49 56
5. Daugan A. P. Grondin C. Ruault A. C. Le Monnier de Gouville H. Coste J. Kirilovsky F. Hyafil R. Labaudiniere 2003 The discovery of tadalafil analogues: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo [1′,5′:1,6] pyrido [3,4-b] indole-1,3(2H)-dione J. Med. Chem. 46 4525 4532
6. Dias-Junior C. A. T. F. Vieira H. Jr. Moreno P. R. Evora J. E. Tanus-Santos 2005 Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary hypertension Pulm. Pharmacol. Ther. 18 181 186
7. Fox P. R. D. Sisson N. S. Moïse 1999 Textbook of Canine and Feline Cardiology: Principles and Clinical Practice 2nd edn Saunders Philadelphia, PA
8. Ghofrani H. A. R. Voswinckel F. Reichenberger H. Olschewski P. Haredza B. Karadas R. T. Schermuly N. Weissmann W. Seeger F. Grimmiger 2004 Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension; a randomized prospective study J. Am. Coll. Cardiol. 44 1488 1496
9. Glaus T. M. K. Tomsa M. Hassig C. Reusch 2004a q16 Echocardiographic changes induced by moderate to marked hypobaric hypoxia in the dog Vet. Radiol. Ultrasound 45 233 237
10. Glaus T. M. G. Soldati R. Maurer F. Ehrensperger 2004b q17 Clinical and pathological characterisation of primary pulmonary hypertension in a dog Vet. Rec. 154 786 789
11. Halcox J. P. K. R. Nour G. Zalos R. A. Mincemoyer M. Waclawiw C. E. Rivera 2002 The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia J. Am. Coll. Cardiol. 40 1232 1240
12. Johnson L. J. Boon E. C. Orton 1999 Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996 J. Vet. Intern. Med. 13 440 447
13. Kittleson M. D. R. D. Kienle 1998 Small Animal Cardiovascular Medicine Mosby Saint Louis, MO
14. Kukreja R. C. R. Ockaili F. Salloum C. Yin J. Hawkins A. Das L. Xi 2004 Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy J. Mol. Cell. Cardiol. 36 165 173
15. Lepore J. J. A. Maroo L. M. Bigatello G. W. Dec W. M. Zapol K. D. Bloch M. J. Semigran 2005 Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide Chest 127 1647 1653
16. Muzzi R. A. L. R. B. De Araùjo L. A. L. Muzzi J. L. B. Pena E. F. Silva 2003 Regurgitant jet area by Doppler color flow mapping: quantitative assessment of mitral regurgitation severity in dogs J. Vet. Cardiol. 5 33 38
17. Palmieri E. A. F. Affuso S. Fazio D. Lembo 2004 Tadalafil in primary pulmonary arterial hypertension Ann. Intern. Med. 141 743 744
18. Sebkhi A. J. W. Strange S. C. Phillips J. Wharton M. R. Wilkins 2003 Phosphodiesterase type 5 as a treatment for hypoxia-induced pulmonary hypertension Circulation 107 3230 3235
19. Seftel A. D. 2004 Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles Clin. Cardiol. 27 14 19
20. Stepien R. L. G. S. Rapoport R. A. Henik L. Wenholz C. B. Thomas 2003 Comparative diagnostic test characteristics of oscillometric and Doppler ultrasonographic methods in the detection of systolic hypertension in dogs J. Vet. Intern. Med. 17 65 72
21. Uehara Y. 1993 An attempt to estimate pulmonary artery pressure in dogs by means of pulsed Doppler echocardiography J. Vet. Med. Sci. 55 307 312
22. Yamamoto T. A. Wada T. Tsutamoto M. Ohnishi M. Horie 2004 Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway J. Cardiovasc. Pharmacol. 44 596 600
23. Zhao L. N. A. Mason J. W. Strange H. Walker M. R. Wilkins 2003 Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity Circulation 107 234 237